Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
We use our state-of-the-art dedicated workflow for designing focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.
Our library stands out due to several important features:
partner
Reaxense
upacc
Q9HB58
UPID:
SP110_HUMAN
Alternative names:
Interferon-induced protein 41/75; Speckled 110 kDa; Transcriptional coactivator Sp110
Alternative UPACC:
Q9HB58; B4DVI4; F5H1M1; Q14976; Q14977; Q53TG2; Q8WUZ6; Q9HCT8
Background:
The Sp110 nuclear body protein, also known as Interferon-induced protein 41/75, Speckled 110 kDa, and Transcriptional coactivator Sp110, plays a pivotal role in the immune system. It functions as a transcription factor and may act as a nuclear hormone receptor coactivator, enhancing the transcription of genes with retinoic acid response elements (RARE).
Therapeutic significance:
Sp110 is directly linked to Hepatic venoocclusive disease with immunodeficiency, a severe condition characterized by hypogammaglobulinemia, combined T and B-cell immunodeficiency, and absence of lymph node germinal centers. Understanding the role of Sp110 could open doors to potential therapeutic strategies for this immunodeficiency.